Contributions
Abstract: PB2029
Type: Publication Only
Background
Rituximab alone or combined with chemotherapy is the treatment of choice for follicular lymphoma and we retrospectively analyzed the impact of PET-CT complete remission (CR) and time to next treatment (TTNT) on outcome of follicular lymphoma patients.
Aims
To investigate the importance of PET-CT CR and TTNT on overall survival.
Methods
Between 2002 and 2014, we have 174 follicular patients treated at our institute and 150 patients can be evaluated the treatment response and long-term outcome.
Results
The CR after first line treatment with either R-COP or R-CHOP is 89% and PR 7% and 10-year overall survival is 62.6%. Eleven percent of patients died of lymphoma and 3% died of other causes. Forty seven patients (31%) underwent second line of treatment with 19 (40%) TTNT shorter than 24 months and 28 (60%) longer than 24 months. There is no difference of overall survival between R-COP (86%) versus R-CHOP (77%) in 5 years, but there is trend to have more next treatment event in R-COP group as compared with R-CHOP group (60% vs 35% on 8-year follow up). There is no difference of overall survival between with or without rituximab maintenance. For PET-CT response, there is significant overall survival difference between CR and PR patients (88% vs 70%, p<0.001), and longer TTNT is seen in initial CR patients. TTNT longer than 24 months have better overall survival as compared with shorter than 24 months patients (93% vs 54% on 5-year).
Conclusion
Initial PET-CT CR patients have better overall survival as compared with PR patients and PET-CT CR should be the treatment goal on initial treatment. Besides, TTNT longer than 24 months patients have better outcome as well.
Session topic: 20. Indolent Non-Hodgkin lymphoma – Clinical
Keyword(s): Follicular lymphoma, PET
Abstract: PB2029
Type: Publication Only
Background
Rituximab alone or combined with chemotherapy is the treatment of choice for follicular lymphoma and we retrospectively analyzed the impact of PET-CT complete remission (CR) and time to next treatment (TTNT) on outcome of follicular lymphoma patients.
Aims
To investigate the importance of PET-CT CR and TTNT on overall survival.
Methods
Between 2002 and 2014, we have 174 follicular patients treated at our institute and 150 patients can be evaluated the treatment response and long-term outcome.
Results
The CR after first line treatment with either R-COP or R-CHOP is 89% and PR 7% and 10-year overall survival is 62.6%. Eleven percent of patients died of lymphoma and 3% died of other causes. Forty seven patients (31%) underwent second line of treatment with 19 (40%) TTNT shorter than 24 months and 28 (60%) longer than 24 months. There is no difference of overall survival between R-COP (86%) versus R-CHOP (77%) in 5 years, but there is trend to have more next treatment event in R-COP group as compared with R-CHOP group (60% vs 35% on 8-year follow up). There is no difference of overall survival between with or without rituximab maintenance. For PET-CT response, there is significant overall survival difference between CR and PR patients (88% vs 70%, p<0.001), and longer TTNT is seen in initial CR patients. TTNT longer than 24 months have better overall survival as compared with shorter than 24 months patients (93% vs 54% on 5-year).
Conclusion
Initial PET-CT CR patients have better overall survival as compared with PR patients and PET-CT CR should be the treatment goal on initial treatment. Besides, TTNT longer than 24 months patients have better outcome as well.
Session topic: 20. Indolent Non-Hodgkin lymphoma – Clinical
Keyword(s): Follicular lymphoma, PET